Roy M Fleischmann


Ontology type: schema:Person     


Person Info

NAME

Roy M

SURNAME

Fleischmann

Publications in SciGraph latest 50 shown

  • 2021-12-17 Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis in RHEUMATOLOGY AND THERAPY
  • 2021-12-08 Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis in RHEUMATOLOGY AND THERAPY
  • 2021-11-23 Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis in RHEUMATOLOGY AND THERAPY
  • 2021-09-25 Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial in ARTHRITIS RESEARCH & THERAPY
  • 2021-09-24 Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis in CLINICAL RHEUMATOLOGY
  • 2020-09-09 Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials in ARTHRITIS RESEARCH & THERAPY
  • 2020-06-10 Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies in ARTHRITIS RESEARCH & THERAPY
  • 2020-03-17 Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial in RHEUMATOLOGY AND THERAPY
  • 2020-01-31 Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et al. in ARTHRITIS RESEARCH & THERAPY
  • 2020-01-16 Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology? in RHEUMATOLOGY AND THERAPY
  • 2019-12-10 Looking Back on 2019 in Rheumatology and What to Expect from 2020 in RHEUMATOLOGY AND THERAPY
  • 2019-11-10 Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials in ARTHRITIS RESEARCH & THERAPY
  • 2019-10-22 Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE) in RHEUMATOLOGY AND THERAPY
  • 2019-01-05 A Summary of 2018 and What Lies Ahead for Rheumatology and Therapy in 2019 in RHEUMATOLOGY AND THERAPY
  • 2018-11-09 Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies in RHEUMATOLOGY AND THERAPY
  • 2018-08-15 A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis in ARTHRITIS RESEARCH & THERAPY
  • 2018-08-04 Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study in CLINICAL RHEUMATOLOGY
  • 2018-02-22 Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis in RHEUMATOLOGY AND THERAPY
  • 2018-02-07 Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis in RHEUMATOLOGY AND THERAPY
  • 2017-11-03 Biosimilars in rheumatology — why, how and when in 2017 in NATURE REVIEWS RHEUMATOLOGY
  • 2017-09-18 Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment in ARTHRITIS RESEARCH & THERAPY
  • 2017-03-28 Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients in RHEUMATOLOGY AND THERAPY
  • 2016-10-12 Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group in CLINICAL RHEUMATOLOGY
  • 2016-10-08 Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis in CLINICAL PHARMACOKINETICS
  • 2015-12-19 Living with Psoriatic Arthritis: A Patient’s and Physician’s Perspective in RHEUMATOLOGY AND THERAPY
  • 2015-11-27 Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity in ARTHRITIS RESEARCH & THERAPY
  • 2015-11-15 Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population in ARTHRITIS RESEARCH & THERAPY
  • 2015-11-04 Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs in ARTHRITIS RESEARCH & THERAPY
  • 2014-11-11 Developing new oral targeted therapies for RA can be challenging in NATURE REVIEWS RHEUMATOLOGY
  • 2014-07-09 Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis in CLINICAL RHEUMATOLOGY
  • 2008-03-07 Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis in BMC MUSCULOSKELETAL DISORDERS
  • 2007-10-19 Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis in ARTHRITIS RESEARCH & THERAPY
  • 2007-08 Primer: establishing a clinical trial unit—obtaining studies and patients in NATURE REVIEWS RHEUMATOLOGY
  • 2007-04 Treatment of osteoarthritis with anakinra in CURRENT RHEUMATOLOGY REPORTS
  • 2007-04 Primer: establishing a clinical trial unit—regulations and infrastructure in NATURE REVIEWS RHEUMATOLOGY
  • 2007-03 Risk: Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis in DRUGS & AGING
  • 2005-08-13 Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib in CLINICAL RHEUMATOLOGY
  • 2005-06 Treatment of early rheumatoid arthritis in MODERN RHEUMATOLOGY
  • 2004-06-21 Does safety make a difference in selecting the right TNF antagonist? in ARTHRITIS RESEARCH & THERAPY
  • 2004-06-21 Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? in ARTHRITIS RESEARCH & THERAPY
  • 2004-02 Pharmacokinetics and pharmacodynamics of a human anti‐TNF‐alpha monoclonal antibody in patients with rheumatoid arthritis in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2003-09-12 Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis in ARTHRITIS RESEARCH & THERAPY
  • 2002-03 Safety and Efficacy of Disease-Modifying Anti-Rheumatic Agents in DRUG SAFETY
  • 1996-02 A Double‐blind, Placebo‐Controlled, Repeated Dose, Dose‐Response Evaluation of Controlled‐Release (CR) Oxycodone in Patients with Osteoarthritis in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.267313.2", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.168645.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.1003.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5606.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10419.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.477482.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.19006.3e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.420220.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6363.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411119.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.107950.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416166.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414065.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416999.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.34477.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416214.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.55460.32", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10041.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.24381.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.17063.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.267323.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.508487.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410566.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7468.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410513.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9909.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9486.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.456065.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413558.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419971.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.62560.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418726.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4714.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.271052.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.451052.7", 
            "type": "Organization"
          }
        ], 
        "familyName": "Fleischmann", 
        "givenName": "Roy M", 
        "id": "sg:person.01065106031.43", 
        "identifier": [
          {
            "name": "orcid_id", 
            "type": "PropertyValue", 
            "value": "0000-0002-6630-1477"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43", 
          "https://orcid.org/0000-0002-6630-1477"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-01-01T19:57", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/person/person_784.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01065106031.43'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01065106031.43'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01065106031.43'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01065106031.43'


     

    This table displays all metadata directly associated to this object as RDF triples.

    89 TRIPLES      11 PREDICATES      47 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.01065106031.43 schema:affiliation Nc627264922f94fe091921e1e9d4397e0
    2 grid-institutes:grid.1003.2
    3 grid-institutes:grid.10041.34
    4 grid-institutes:grid.10419.3d
    5 grid-institutes:grid.107950.a
    6 grid-institutes:grid.168645.8
    7 grid-institutes:grid.17063.33
    8 grid-institutes:grid.19006.3e
    9 grid-institutes:grid.24381.3c
    10 grid-institutes:grid.267323.1
    11 grid-institutes:grid.271052.3
    12 grid-institutes:grid.34477.33
    13 grid-institutes:grid.410513.2
    14 grid-institutes:grid.410566.0
    15 grid-institutes:grid.411119.d
    16 grid-institutes:grid.413558.e
    17 grid-institutes:grid.414065.2
    18 grid-institutes:grid.416166.2
    19 grid-institutes:grid.416214.4
    20 grid-institutes:grid.416999.a
    21 grid-institutes:grid.418726.e
    22 grid-institutes:grid.419971.3
    23 grid-institutes:grid.420220.6
    24 grid-institutes:grid.451052.7
    25 grid-institutes:grid.456065.4
    26 grid-institutes:grid.4714.6
    27 grid-institutes:grid.477482.a
    28 grid-institutes:grid.508487.6
    29 grid-institutes:grid.55460.32
    30 grid-institutes:grid.5606.5
    31 grid-institutes:grid.62560.37
    32 grid-institutes:grid.6363.0
    33 grid-institutes:grid.7468.d
    34 grid-institutes:grid.9486.3
    35 grid-institutes:grid.9909.9
    36 schema:familyName Fleischmann
    37 schema:givenName Roy M
    38 schema:identifier Na9f6ba8f190146fe95be019c046069cd
    39 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43
    40 https://orcid.org/0000-0002-6630-1477
    41 schema:sdDatePublished 2022-01-01T19:57
    42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    43 schema:sdPublisher Ndf1ef0c6622844b7a526f4bd60dff17c
    44 sgo:license sg:explorer/license/
    45 sgo:sdDataset persons
    46 rdf:type schema:Person
    47 Na9f6ba8f190146fe95be019c046069cd schema:name orcid_id
    48 schema:value 0000-0002-6630-1477
    49 rdf:type schema:PropertyValue
    50 Nc627264922f94fe091921e1e9d4397e0 schema:affiliation grid-institutes:grid.267313.2
    51 sgo:isCurrent true
    52 rdf:type schema:OrganizationRole
    53 Ndf1ef0c6622844b7a526f4bd60dff17c schema:name Springer Nature - SN SciGraph project
    54 rdf:type schema:Organization
    55 grid-institutes:grid.1003.2 schema:Organization
    56 grid-institutes:grid.10041.34 schema:Organization
    57 grid-institutes:grid.10419.3d schema:Organization
    58 grid-institutes:grid.107950.a schema:Organization
    59 grid-institutes:grid.168645.8 schema:Organization
    60 grid-institutes:grid.17063.33 schema:Organization
    61 grid-institutes:grid.19006.3e schema:Organization
    62 grid-institutes:grid.24381.3c schema:Organization
    63 grid-institutes:grid.267313.2 schema:Organization
    64 grid-institutes:grid.267323.1 schema:Organization
    65 grid-institutes:grid.271052.3 schema:Organization
    66 grid-institutes:grid.34477.33 schema:Organization
    67 grid-institutes:grid.410513.2 schema:Organization
    68 grid-institutes:grid.410566.0 schema:Organization
    69 grid-institutes:grid.411119.d schema:Organization
    70 grid-institutes:grid.413558.e schema:Organization
    71 grid-institutes:grid.414065.2 schema:Organization
    72 grid-institutes:grid.416166.2 schema:Organization
    73 grid-institutes:grid.416214.4 schema:Organization
    74 grid-institutes:grid.416999.a schema:Organization
    75 grid-institutes:grid.418726.e schema:Organization
    76 grid-institutes:grid.419971.3 schema:Organization
    77 grid-institutes:grid.420220.6 schema:Organization
    78 grid-institutes:grid.451052.7 schema:Organization
    79 grid-institutes:grid.456065.4 schema:Organization
    80 grid-institutes:grid.4714.6 schema:Organization
    81 grid-institutes:grid.477482.a schema:Organization
    82 grid-institutes:grid.508487.6 schema:Organization
    83 grid-institutes:grid.55460.32 schema:Organization
    84 grid-institutes:grid.5606.5 schema:Organization
    85 grid-institutes:grid.62560.37 schema:Organization
    86 grid-institutes:grid.6363.0 schema:Organization
    87 grid-institutes:grid.7468.d schema:Organization
    88 grid-institutes:grid.9486.3 schema:Organization
    89 grid-institutes:grid.9909.9 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...